Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2020 - 12 - 01 save search
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Published: 2020-08-03 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: 2.39%
H: 8.1%
C: 5.76%
conference presentation
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Published: 2020-08-05 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: 1.31%
H: 4.89%
C: 2.88%
phase 3 treatment enroll
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
Published: 2020-08-06 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: -12.45%
results
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Published: 2020-09-08 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: -75.89%
H: 9.87%
C: 0.0%
results sclerosis phase 3 treatment topline
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
Published: 2020-10-06 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: -41.27%
H: 15.32%
C: 9.01%
treatment phase 2b fibrosis cystic fibrosis
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
Published: 2020-10-08 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: -2.48%
H: 6.78%
C: 4.24%
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
Published: 2020-10-21 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: 2.08%
H: 1.0%
C: -5.88%
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
Published: 2020-10-23 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: -1.44%
H: 6.34%
C: -1.46%
phase 2b fibrosis cystic fibrosis
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
Published: 2020-11-03 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: 0.98%
H: 5.83%
C: 3.88%
results
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
Published: 2020-11-09 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: 2.65%
H: 5.17%
C: 5.17%
sclerosis
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
Published: 2020-11-10 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: -2.62%
H: 2.69%
C: 2.69%
results
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Published: 2020-11-12 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3
|
Health Technology
|
| O: 0.0%
H: 29.51%
C: 13.11%
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020
Published: 2020-05-18 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
results
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Published: 2020-05-29 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
cancer positive phase 3 prostate cancer cardio cardiovascular
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Published: 2020-06-01 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
fda drug new drug treatment application
Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
cancer fda drug prostate cancer fda acceptance new drug
Myovant Sciences to Host Webcast and Conference Call at 8:30 am Eastern Time Tuesday, June 23 to Discuss Results from Phase 3 SPIRIT 1 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
therapy results phase 3
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2020-06-23 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
therapy positive results positive results phase 3
BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer
Published: 2020-06-30 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
cancer research prostate cancer
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study
Published: 2020-07-06 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
therapy phase 3
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
MTH | $154.69 -2.21% 7.56% 64
|
Consumer Durables
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
IHT P | $1.3712 0.82% 6.48% 0
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.